Narcolepsy Drugs Market to Garner $5.36 Bn, Globally, by 2026 at 10.3% CAGR: Says Allied Market Research

Increase in prevalence of narcolepsy across the globe, surge in narcolepsy awareness programs, and presence of reimbursement policies regarding narcolepsy are expected to propel the growth of the global narcolepsy drugs market

News provided by

Allied Market Research

Jul 16, 2019, 06:30 ET

PORTLAND, Oregon, July 16, 2019 /PRNewswire/ -- Allied Market Research recently published a report, titled, "Narcolepsy Drugs Market by Disease Type (Daytime Extreme Sleepiness, Cataplexia, and Others) and Therapeutics Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026". According to the report, the global narcolepsy drugs market was pegged at $2.43 billion in 2018 and is projected to reach $5.36 billion by 2026, registering a CAGR of 10.3% from 2019 to 2026.

Rise in the global prevalence of narcolepsy, presence of reimbursement policies regarding narcolepsy, and narcolepsy awareness programs and services have boosted the growth of the narcolepsy drugs market. However, adverse effects and risks related to narcolepsy drugs and delayed diagnosis or misdiagnosis hamper the market growth. On the contrary, untapped markets in developing countries are expected to create lucrative opportunities in the near future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/3612

Daytime extreme sleepiness segment dominated the market

The daytime extreme sleepiness segment held the largest share in 2018, contributing nearly half of the market, owing to rise in prevalence of narcolepsy and other sleep disorders. However, the cataplexia segment is estimated to 10.7% during the forecast period, as patients suffering from cataplexia tend to lose muscle control and around 70% of narcolepsy patients have this symptom.

Selective serotonin reuptake inhibitor segment to manifest fastest growth

The selective serotonin reuptake inhibitor segment is estimated to portray the fastest CAGR of 11.3% during the forecast period, owing to increase in R&D activities for the development of these type of drugs by the key players. However, the sodium oxybate segment dominated the market in 2018, accounting for more than half of the market, as these drugs are highly effective to treat daytime extreme sleepiness and cataplexy.

Asia-Pacific region to portray fastest growth through 2026

The market across the Asia-Pacific region is expected to register the fastest CAGR of 11.4% during the forecast period, owing to increase in prevalence of narcolepsy and surge in adoption rate of narcolepsy drugs. However, the market across North America held the lion's share in 2018, contributing more than two-fifths of the market, owing to rise in number of narcolepsy and other sleep disorders in North America.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/3612

Major market players

The report provides an in-depth analysis of the key market players such as Addrenex Pharmaceuticals, Ligand Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Shire Plc, Jazz Pharmaceuticals Plc., Arena Pharmaceuticals, Graymark Healthcare, Inc., and Bioprojet.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Drug Abuse Testing Market: Global Opportunity Analysis and Industry Forecast, 2018 - 2025

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-6634606
Fax: +1(855)550-5975
[email protected]